Riskpilot← Back to searchSign inGet full accessASTELLAS PHARMA A/S
A/SActiveCVR 10888638Arne Jacobsens Allé 15Wholesale of pharmaceutical and medical goods · NACE 4646Est. 198770 employees
Revenue 2025
DKK 191M
+2% vs 2024
EBITDA margin
3.1%
-2% vs 2024
Equity ratio
18.9%
Financial strength
Net profit 2025
DKK 5,7M
+28% vs 2024
| Revenue | DKK 191M | +2% |
| EBITDA | DKK 5,9M | -2% |
| Net profit | DKK 5,7M | +28% |
| Total assets | DKK 110M | +9% |
| Equity | DKK 20,8M | -16% |
| Employees | 70 | — |
Legal name
ASTELLAS PHARMA A/S
CVR number
10888638
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
1. juli 1987
Share capital
DKK 600.000
Employees
70 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-03-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to medlemmer af bestyrelsen i forening, af et medlem af bestyrelsen og en direktør eller af to direktører eller af den samlede bestyrelse.
Company purpose
Selskabets formål er: at etablere, at erhverve og at finansiere, at deltage i og udføre management i andre virksomheder, at handle med produkter indenfor fødevare-, sundheds- og miljøområdet, at udvikle og/eller at producere sådanne produkter, alt i videste forstand, at erhverve og afhænde immaterialrettigheder og at udøve enhver handling, som er knyttet til eller er en konsekvens af det foranstående i videst muligt omfang.
Address
Arne Jacobsens Allé 15
Phone
+4543430355
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 92.965 | 97.029 | 121.936 | 155.987 | 144.927 | 157.806 | 182.590 | 187.005 | 160.457 | 179.933 | 180.837 | 186.855 | 191.027 |
| Staff expenses | -15.543 | -16.242 | -17.480 | -16.875 | -14.406 | -15.621 | -18.393 | -18.231 | -17.530 | -16.971 | -17.877 | -14.894 | -18.559 |
| EBITDA | 8.017 | 10.293 | 8.366 | 210 | 3.488 | 4.870 | 6.626 | 5.612 | 5.358 | 9.161 | 5.224 | 5.993 | 5.852 |
| Depreciation & amort. | -259 | -260 | -224 | -200 | -165 | -101 | 118 | -124 | -170 | -147 | -126 | -61 | -60 |
| EBIT | 7.758 | 10.033 | 8.142 | 10 | 3.323 | 4.769 | 6.508 | 5.488 | 5.188 | 9.014 | 5.098 | 5.932 | 5.792 |
| Net financials | 242 | -541 | -493 | -707 | -288 | -1.340 | -291 | -2.775 | 2.656 | 125 | -2.195 | 86 | 1.728 |
| Profit before tax | 8.000 | 9.492 | 7.649 | 8.913 | 3.035 | 3.429 | 6.217 | 2.713 | 7.844 | 9.139 | 2.903 | 6.018 | 7.520 |
| Tax | 2.286 | 2.503 | 2.391 | 2.257 | -1.342 | 867 | 1.482 | 677 | 1.979 | 2.450 | 822 | 1.548 | 1.815 |
| Net profit | 5.714 | 6.989 | 5.258 | 6.656 | 12.189 | 2.562 | 4.735 | 2.036 | 5.865 | 6.689 | 2.081 | 4.470 | 5.705 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 44.705 | 50.410 | 79.572 | 85.538 | 82.219 | 103.234 | 129.628 | 126.991 | 145.455 | 345.591 | 112.042 | 100.770 | 109.956 |
| Equity | 34.448 | 38.437 | 38.694 | 45.351 | 51.540 | 54.102 | 56.236 | 53.572 | 59.437 | 58.226 | 35.307 | 24.696 | 20.814 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 10.257 | 11.973 | 40.878 | 40.187 | 30.679 | 49.132 | 73.392 | 73.413 | 85.972 | 287.365 | 76.735 | 76.057 | 89.120 |
| Total debt | 10.257 | 11.973 | 40.878 | 40.187 | 30.679 | 49.132 | 73.392 | 73.413 | 85.972 | 287.365 | 76.735 | 76.057 | 89.120 |
EBITDA margin
3.1%
This company
15.8%
Market median
-80% vs market
20132025
Equity ratio
18.9%
This company
38.2%
Market median
-51% vs market
20132025
Return on equity
27.4%
This company
18.4%
Market median
+49% vs market
20132025
Net profit margin
3.0%
This company
8.1%
Market median
-63% vs market
20132025
Asset turnover
1.74×
This company
1.12×
Market median
+55% vs market
20132025
Debt / equity
4.28×
This company
0.62×
Market median
-590% vs market
20132025
- Annual report 2025Filed via CVR / Virk · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via CVR / Virk · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via CVR / Virk · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via CVR / Virk · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via CVR / Virk · Period 2020-04-01 – 2021-03-31
- Annual report 2020Filed via CVR / Virk · Period 2019-04-01 – 2020-03-31
- Annual report 2019Filed via CVR / Virk · Period 2018-04-01 – 2019-03-31
- Annual report 2018Filed via CVR / Virk · Period 2017-04-01 – 2018-03-31
- Annual report 2017Filed via CVR / Virk · Period 2016-04-01 – 2017-03-31
- Annual report 2016Filed via CVR / Virk · Period 2015-04-01 – 2016-03-31
- Annual report 2015Filed via CVR / Virk · Period 2014-04-01 – 2015-03-31
- Annual report 2014Filed via CVR / Virk · Period 2013-04-01 – 2014-03-31
- Annual report 2013Filed via CVR / Virk · Period 2012-04-01 – 2013-03-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MA Management | Management | 2025 | — | — |
KH Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
JA Chief Executive Officer | Chief Executive Officer | 2016 | — | — |
| Audit | 1987 | — | — | |
ET | Audit | 1987 | — | — |
SA Management | Management | 1987 | — | — |
PT Chief Executive Officer | Chief Executive Officer | 2019 | — | — |
MS Chief Executive Officer | Chief Executive Officer | 2005 | — | — |
HL Management | Management | 2004 | — | — |
BN Management | Management | 1987 | — | — |
PE Management | Management | 1987 | — | — |
MA Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 1987 | — | — | |
| Chairman | 2016 | — | — | |
| Chairman | 2001 | — | — | |
| Chairman | 2002 | — | — | |
| Board of Directors | 1987 | — | — | |
| Board of Directors | 1987 | — | — | |
| Board of Directors | 1998 | — | — | |
| Chairman | 2010 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2005 | — | — | |
| Board of Directors | 1987 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2000 | — | — | |
| Chairman | 2022 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 1987 | — | — | |
| Board of Directors | 1987 | — | — | |
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2005 | — | — | |
| Board of Directors | 1987 | — | — | |
| Board of Directors | 2007 | — | — | |
| Board of Directors | 1998 | — | — | |
| Chairman | 1987 | — | — | |
| Board of Directors | 1987 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ASTELLAS PHARMA A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mark Andree Dekker | Management | 0 companies |
| Karl Håkan Lennart Widen | Chief Executive Officer | 0 companies |
| Jan Anders Martin Nordén | Chief Executive Officer | 0 companies |
| Arthurg Young & Company Intern ational | Audit | 0 companies |
| Erik Tronborg Andersen | Audit | 0 companies |
| Stead Arthur Ellis | Management | 0 companies |
| Pia Terésa Lindkvist | Chief Executive Officer | 0 companies |
| Mats Stefan Persson | Chief Executive Officer | 0 companies |
| Herman Levinus Pierre Breepoel | Management | 0 companies |
| Berend Nico Huisman | Management | 0 companies |
| Per Emil Hasselbalch Stakemann | Management | 0 companies |
| Morten Auscher | Chief Executive Officer | 0 companies |
| Arend Paasman | Board of Directors | 0 companies |
| Pedro Møllebro | Chairman | 0 companies |
| Yasuo Ishii | Chairman | 0 companies |
| Wilhelmus Jacques Josephus Kockelkoren | Chairman | 0 companies |
| Ulf Svejgaard Poulsen | Board of Directors | 0 companies |
| Simon Johannes Quist | Board of Directors | 0 companies |
| Philippe Andre Pierre Ballero | Board of Directors | 0 companies |
| Nicolaas Jacobus Stander | Chairman | 0 companies |
| Rowena Borenstein | Board of Directors | 0 companies |
| Gillian Kay Mitchell | Board of Directors | 0 companies |
| Masakatsu Inoue | Board of Directors | 0 companies |
| Malene Abildstrøm | Board of Directors | 0 companies |
| Johannes Adrianus de Heus | Board of Directors | 0 companies |
| Damla Ebru Atilgan | Chairman | 0 companies |
| Yagnaram Santharam | Chairman | 0 companies |
| Shigekazu Takahashi | Board of Directors | 0 companies |
| Henricus Johannes Huiberts | Board of Directors | 0 companies |
| Niels Walther-Rasmussen | Board of Directors | 0 companies |
| Hiroshi Nogawa | Board of Directors | 0 companies |
| Andre Louis De Haas | Board of Directors | 0 companies |
| Seiji Kinoshita | Board of Directors | 0 companies |
| Douwe Wybe Witteveen | Board of Directors | 0 companies |
| Susanne Saul Stakemann | Chairman | 0 companies |
| Arnold Johan Westerveld | Board of Directors | 0 companies |